Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Skye Bioscience Inc.

Skye Bioscience to Present at Upcoming Investment Conferences
Skye Bioscience Uplists to The Nasdaq Global Market
Skye Bioscience Announces $40 Million Private Placement Equity Financing
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
Skye Bioscience to Present at Oppenheimer Investor Conference
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.